



Incontri Bresciani di Radioterapia Oncologica – Edizione 2014
Brescia Meetings in Radiation Oncology – 2014 Edition

NORTHWEST PASSAGE: KEY-FUNCTIONS PRESERVATION IN ONCOLOGY


Brescia – September 25th/26th, 2014

Imaging of cardio-pulmonary treatment related damage

Dr. Andrea Borghesi


Dr. Emanuele Gavazzi

Department of Radiology 2 – University of Brescia




Radiotherapy and Lung


- The goal of radiation therapy (RT) is to **reduce or eliminate the tumor** with minimal toxicity to normal surrounding tissue
- RT is used to treat many intrathoracic and chest wall malignancies (**breast cancer, bronchogenic carcinoma, oesophageal neoplasm, malignant mesothelioma and lymphoma**)



Breast cancer → 3D-CRT



NSCLC → IMRT



Oesophageal cancer → IMRT



Radiation-induced lung injury (RILI)

- The lung is one of the most sensitive tissue to ionizing radiation and damage to normal lung tissue remains the main obstacle in RT
- Radiation-induced lung disease (RILD) is a frequent complication of RT (*40% of patients develop radiographic abnormalities - 7% develop symptomatic pneumonitis*)
- Radiation-induced changes in the lung are dependent on a number of factors including:
 - *Patient-specific factors* (age, smoking, pre-existing lung disease)
 - *RT technique* (3D CRT, IMRT e SBRT)
 - *Radiation dose*
 - *Volume of lung irradiated*
 - *Administration of chemotherapy*

Benveniste MFK et al Clinical Radiol 2013; Graves PR et al Semin Radiat Oncol 2010
Mesurolle B et al Radiographics 2000; Park et al Radiographics 2000; Jennings FLAA 1962



Radiation-induced lung disease (RILD)


- Two distinct clinical, pathologic, and radiologic phases of RILD are recognized:
 - Acute phase (*Radiation Pneumonitis* → *4-12 weeks after RT*)
 - Chronic phase (*Radiation Fibrosis* → *several months after RT*)
- Depending on the severity of lung injury, these abnormalities may resolve completely, but they more often undergo progressive organization and eventually lead to fibrosis

Benveniste MFK et al Clinical Radiol 2013; Park et al Radiographics 2000;
Larici AR et al Radiographics 2011



Usual Radiologic Findings after RT



- **RILD** is not generally seen with doses below 20Gy and it is most commonly seen with doses $> 40\text{Gy}$.
- Radiologic manifestations of RILD, generally confined to the field of irradiation, are **better detected on CT** than chest radiographs



Usual Radiologic Findings after RT

- **Acute phase (Radiation Pneumonitis)**

- **Chest X-ray**
 - Diffuse haziness
 - Consolidation
 - Pleural effusion
 - Elevation of diaphragm






Usual Radiologic Findings after RT

- Acute phase (Radiation Pneumonitis)

- CT (more sensitive)
 - Ground-glass opacity
 - Patchy or dense consolidation
 - Pleural effusion




Benveniste MFK et al Clinical Radiol 2013;



Usual Radiologic Findings after RT

- Chronic phase (Radiation Fibrosis)

- Chest X-ray
 - Linear opacities
 - Dense consolidation
 - Architectural distortion
 - Volume loss
 - Shift of the mediastinum
 - Elevation of diaphragm






Usual Radiologic Findings after RT

- **Chronic phase (Radiation Fibrosis)**

- CT (more sensitive)
 - Steeple opacities
 - Dense consolidation
 - Traction bronchiectasis
 - Architectural distortion
 - Volume loss
 - Pleural thickening
 - Shift of the mediastinum
 - Elevation of diaphragm




Benveniste MFK et al Clinical Radiol 2013; Graves PR et al Semin Radiat Oncol 2010




Usual Radiologic Findings after RT

- **Acute and chronic phase**


- 53 year-old female with mucoepidermoid carcinoma of the tracheal carina



Before RT



1 month after RT



1 year after RT



Unusual Radiologic Findings after RT

| Target Organ | Complication | Time to Onset | Fractionated Dose | Reference |
|--------------|--------------|------------------------------------|---|---------------------------|
| Lung | Pneumonitis | 1–3 mo (acute), 12–15 mo (late) | 30 Gy | Mosvas et al (3) |
| | Necrosis | 12 mo (1–7 y for cavitations) | >60 Gy | ... |
| | BOOP* | 6 wk to 10 mo | Breast carcinoma irradiation; no minimal dose defined | Crestani et al (4) |
| | Pneumothorax | 16 mo | >30 Gy | Penniment and O'Brien (5) |

- **Necrosis**: uncommon (0.6%), severe and late complication after RT (>60 Gy)
- **Cavitation** within the radiation fibrosis may also indicate an **infectious process** (including TBC) and **recurrent tumour**

Mesurrolle B et al Radiographics 2000



Unusual Radiologic Findings after RT

| Target Organ | Complication | Time to Onset | Fractionated Dose | Reference |
|--------------|--------------|------------------------------------|---|---------------------------|
| Lung | Pneumonitis | 1–3 mo (acute), 12–15 mo (late) | 30 Gy | Mosvas et al (3) |
| | Necrosis | 12 mo (1–7 y for cavitations) | >60 Gy | ... |
| | BOOP* | 6 wk to 10 mo | Breast carcinoma irradiation; no minimal dose defined | Crestani et al (4) |
| | Pneumothorax | 16 mo | >30 Gy | Penniment and O'Brien (5) |


- **Pneumothorax (1%)**: usually occurs in patients with radiologic evidence of post-irradiation fibrosis
- **BOOP (2.5%)**: patchy, bilateral and multifocal migratory lung opacities (consolidation and ground glass infiltration)

Mesurrolle B et al Radiographics 2000; Kano et al. Jpn J Radiol 2012



Unusual Radiologic Findings after RT

- **BOOP**: patchy, bilateral and multifocal migratory lung opacities (consolidation and ground glass infiltration)



Kano et al. Jpn J Radiol 2012




Differential diagnosis considerations

- When radiological manifestations of radiation damage are different from the expected patterns, other disease entities have to be considered
 - **Infection**
 - *Before completion of RT*
 - *Abrupt onset*
 - *Lung opacities outside of the treated areas*
 - *Tree in bud pattern*
 - **Recurrent tumor**
 - *Occurs within 2 years after RT is completed*
 - *Development of a lobulate contour within the fibrosis*
 - *PET-CT improved DD between recurrent tumour and radiation fibrosis*
(PET-CT is best performed 6 months after RT is completed)**



Recurrent tumor within fibrosis PET-TC

recurrent tumor 18 months after RT



Focal FDG uptake is suggestive of residual or recurrent disease



Conclusions

- RT is an important modality in the treatment of patients with neoplasms.
- Knowledge of pulmonary abnormalities related to RT is important to recognize **patterns of RILD** and detect complications, such as **recurrent malignancy or infection**.



Heart and RT: epidemiology

- Cardiovascular disease is now the **most common non-malignancy cause of death** in radiation-treated cancer survivors (**Hodgkin's lymphoma** and **breast cancer**), most often occurring **decades** after treatment (3 to 29 years after treatment).
- The **long-term effects** on the heart still remain **unclear**, mandating longer follow-up.
- **Increased risk** of coronary artery disease (CAD), congestive heart failure, valvular heart disease, pericardial disease, and sudden death.

Aleman BM et al. J Clin Oncol 2003;21:3431-9. Ng AK. Br J Haematol 2011;154:23-31.
Hoppe RT. Ann Oncol 1997; Suppl 1:115-8. Patnaik JL et al. Breast Cancer Res 2011;13:R64.




Table 2 Effects of Radiation Therapy on the Heart

Vascular

Coronary artery disease

Microvascular dysfunction

Structural

Valvular heart disease

Mitral stenosis and insufficiency

Aortic stenosis and insufficiency

Pericardial disease

Conduction system disease

Myocardial


Systolic dysfunction/systolic heart failure

Diastolic dysfunction/heart failure with preserved ejection fraction

Restrictive cardiomyopathy

Myocardial fibrosis/scar


Jaworski et al. JACC Vol. 61, No. 23, 2013






Prevention and follow-up

- **Before** radiotherapy: **comprehensive baseline evaluation** including a detailed cardiovascular history, cardiac examination, risk factor profiling, and echocardiography (systolic and diastolic function).
- Prolonged cardiological **follow-up** and cardiac **screening** is **mandatory** in cancer patients who have received irradiation to facilitate **early identification** of cardiac related **complications**.
- Control and minimize cardiac **risk factors**



Prevention and follow-up





- There is **a paucity of data** to support the optimal method and frequency of **screening post-radiotherapy patients**
- Development of a **uniform approach** to be potentially beneficial
- The focus of screening should ideally incorporate **non-invasive, radiation-free modalities** in the first instance






Cardiac imaging

- Rest and stress **echocardiography**
- Cardiac magnetic resonance imaging (**CMRI**)
- Coronary computerized topography (**CCT**)


| Structure | Abnormality | Natural History | Pathology |
|--|-----------------|---|---|
| Pericardium  | Pericarditis | Chronic asymptomatic effusion and/or pericarditis with symptoms: hemodynamic compromise with either constriction or tamponade | Fibrous thickening and fluid production |
| Myocardium  | Myocarditis | Progressive diastolic dysfunction and restrictive hemodynamics with symptoms. CHF | Diffuse interstitial fibrosis/ microcirculatory damage leading to capillary obstruction/extensive fibrosis |
| Endocardium  | Valvular damage | Over time, progressive stenosis and regurgitation | Cusp and/or leaflet fibrosis |
| Vascular System  | Arteritis | Premature CAD/accelerated atherosclerosis Pulmonary hypertension | Ostial and proximal stenosis: LAD, RCA, and left main more than left circumflex Pathology similar to atherosclerosis |
| Conduction System | | All forms of heart block and conduction delay | Fibrosis of conduction system |
| Autonomic Dysfunction | | Supraventricular tachycardia; heart rate variability | |

Feng M et al. Int J Radiat Oncol Biol Phys. 2011 January 1; 79(1): 10–18.



CMRI: sequences




- **Morfology**
black blood (HASTE, TSE T1, STIR T2)
bright blood (True FISP)
- **Function**
cine SSFP, Gradient-Echo
- **Tissue characterization** (delayed enhancement)
segmented IR fast GE
- **Perfusion**
- **Valvular Flow**
phase contrast








Morfology: acute and chronic pericarditis

black blood (HASTE, TSE T1, STIR T2)
bright blood (True FISP)




Morfology: acute and chronic pericarditis








Tissue Characterization: edema and inflammation

- Myocarditis: STIR T2 sequence




Tissue Characterization: scar

- Delayed enhancement segmented IR fast GE - PSIR







Tissue characterization: T1 mapping







With or without contrast medium

T1 value and extracellular volume: correlate with myocardial fibrosis



Valvular disease: thickening, stenosis and regurgitation

- Cine and Phase contrast sequences







Coronary CT

- Calcium scoring: Agatstone score





| Artery | Lesions | Volume [mm ³] | Equiv. Mass [mg] | Score |
|--------------|----------|---------------------------|------------------|--------------|
| LM | 0 | 0.0 | 0.00 | 0.0 |
| LAD | 2 | 99.8 | 10.00 | 105.6 |
| CI | 0 | 0.0 | 0.00 | 0.0 |
| CCA | 1 | 1.3 | 0.29 | 0.0 |
| TOTAL | 3 | 101.7 | 10.29 | 105.6 |





Coronary CT

- Detection of asymptomatic CAD





CCT Dose



Conclusions

- The use of **non-invasive, non-radiation-based techniques** such as **echocardiography** and cardiac **MRI** provide an opportunity for regular assessment of the heart for the myocardial, valvular, and pericardial complications of thoracic irradiation.
- **CCT** for detection of CAD is a potential focus for further research.

